Evolent Health (EVH) In Sale Talks After Inbound Interest - Reuters
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Truist Securities Reiterates Buy Rating on Evolent Health (EVH)
August 23, 2024 7:02 AM EDTTruist Securities analyst Jailendra Singh reiterated a Buy rating and $33.00 price target on Evolent Health (NYSE: EVH).
The analyst comments "Bottom Line. M&A discussions related to EVH, whether in part of whole, is not a foreign discussion to the company. However, we... More
Piper Sandler Reiterates Overweight Rating on Evolent Health (EVH)
August 22, 2024 3:59 PM EDTPiper Sandler analyst Jessica Tassan reiterated an Overweight rating and $38.00 price target on Evolent Health (NYSE: EVH).
The analyst comments "Reuters reports that EVH is weighing sale, following takeover interest. The publication states that EVH has received initial offers and that potential acquirers could include PE firms or ELV (not covered) in combination with a PE partner. Our thoughts on today's news. 1. EVH is defining and dominating the market for value-based specialty care management. This is a $732B TAM which we define our white paper on the space here. 2. EVH has assembled best-in-class... More
BTIG Reiterates Buy Rating on Evolent Health (EVH)
August 22, 2024 3:57 PM EDTBTIG analyst David Larsen reiterated a Buy rating and $45.00 price target on Evolent Health (NYSE: EVH)
The analyst comments "Shares of EVH are trading up due to an article in Reuters, stating that several private equity firms, and at least one large health plan, are in discussions to potentially acquire EVH. The press report highlights that a process started after EVH received in-bound... More
